www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

USEUROPEAFRICAASIA 中文雙語Fran?ais
China
Home / China / Across America

Race for an Ebola vaccine is heating up, and in a good way

By Chris Davis | China Daily USA | Updated: 2014-12-23 12:29

China announced late last week that its Academy of Military Medical Sciences has developed an Ebola vaccine that has been approved to enter the human test stage. The drug is specifically designed to target the strain of Ebola that has killed more than 7,370 people - with more than 18,000 confirmed cases - in West Africa in recent months.

"This follows American and Canadian vaccines to become the third Ebola vaccine to enter clinical trials," Xinua reported on Dec 18. There was no official word on when Phase I clinical trials would begin, but other media outlets were saying it could be as early as this month.

The two front runners so far are British pharma giant GlaxoSmithKline and a Canada-based joint project between Merck & Co and NewLink Genetics Corp, both of which are already in clinical trials, Reuters reported.

The Merck-NewLink study, which is being held in Geneva, hit a bump in the road last week when four of the 59 people participating reported joint pain in their feet and hands and the injection schedule was shut down. The clinic said, however, that joint pain was common in these kinds of tests and the injections would resume in January.

The GalxoSmithKline Phase I tests - being conducted in Great Britain, Mali, the US and Switzerland - also had its issues, with 80 percent of volunteers reportedly having some kind of an adverse though mild event at the high dose, a reaction Ebola researcher Dr Thoman Geisbert of the University of Texas said "was kind of surprising".

Nevertheless, GalaxoSmithKline's Ebola vaccine is expected to move into the second, larger scale phase in February, which is later than was previously expected, because health officials from the countries where the trials were planned - Senegal, Nigeria, Mali, Cameroon and Ghana - requested more data on the compound, the World Health Organization reported.

A statement from WHO did not specify exactly what information the countries wanted, but added that "If these steps are completed to the satisfaction of the national authorities, Phase II trials are likely to begin in February".

To further heat up the race, US President Barack Obama last week signed into law a small bill that could have a big impact on the effort. Entitled "Adding Ebola to the FDA Priority Review Voucher Program Act", the new law basically offers fast track priority review vouchers for drugs being developed to combat Ebola and other pathogens in the filovirus family.

The voucher is in effect a promise that the US Food and Drug Administration will process the licensing application within six months. It doesn't guarantee it will be approved, only reviewed and swiftly by the agency's notoriously glacial pace.

Which, of course, can lead to big profits for a drug company, if it can get its product to market before a competitor, get into pharmacies first and be there longer with patent protection. "The monetary gains could be huge, much more than $125 million," Rui Sanjuan, manager and legal policy adviser for Doctors Without Borders, told the Canadian Press.

Started in 2007, the priority voucher program is an effort to entice pharmaceutical companies to develop treatments for diseases that usually don't attract industry attention because of dim prospects for profits, according to the NIH.

Race for an Ebola vaccine is heating up, and in a good way

On Monday, the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services announced it was awarding a grant of $30 million to the NewLink/Merck effort.

The grant will ramp up production of the vaccine and support a 330-person study once the vaccine clears the smaller Phase I trials and is proven safe.

"The current funding provided by BARDA is key to the rapid development of this Ebola vaccine candidate," said Dr Charles Link, CEO and chief science officer of Ames, Iowa-based NewLink. "These funds will support multiple facets of the accelerated Ebola vaccine program including the expansion of critical vaccine supplies and larger clinical studies."

Dr Mark Feinberg, chief public health and science officer at Merck Vaccines, said: "Governments and industry are effectively collaborating in an unprecedented effort to accelerate the development of Ebola vaccine candidates."

News of the grant sent NewLink Genetics' (NLNK) stock price surging 2.7 percent on the Nasdaq. Merck traded down 0.5 percent.

China's announcement of its own Ebola vaccine noses out Johnson & Johnson, which was expected to announce clinical trials shortly and become the third horse in the race. Chinese biotech firm Tianjin CanSino Biotechnology is also developing an Ebola vaccine.

Contact the writer at chrisdavis@chinadailyusa.com.

Polar icebreaker Snow Dragon arrives in Antarctic
Xi's vision on shared future for humanity
Air Force units explore new airspace
Premier Li urges information integration to serve the public
Dialogue links global political parties
Editor's picks
Beijing limits signs attached to top of buildings across city
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 国产成人午夜精品影院游乐网 | 99精品视频在线观看免费 | 日韩精品永久免费播放平台 | 久久偷看各类wc女厕 | 九色国产在线 | 日本加勒比在线播放 | 国产一级做a爰片在线看 | 日本免费一区二区三区a区 日本免费一区二区三区看片 | 日本草草视频在线观看 | 国产日产欧产精品精品推荐小说 | 特级毛片永久久免费观看 | 中国成人在线视频 | 91视频站 | 日本一区二区三区四区五区 | 精品九九久久国内精品 | 巨乳毛片| 国产一级二级三级毛片 | 99热久久精品免费精品 | 成人在线毛片 | 免费在线观看黄色毛片 | 久揄揄鲁一二三四区高清在线 | 亚洲精品男人天堂 | 91精品啪在线看国产网站 | 欧美精品免费看 | 中文字幕在线无限2021 | 97capcom超频在线 | 国产一级爱c片免费播放 | 成人自拍视频 | 一区二区三区国产精品 | 99久久精品免费看国产免费 | 久久国产精品久久 | 黄色a∨| 中文字幕亚洲一区二区v@在线 | 亚洲国产高清一区二区三区 | 欧美精品一区二区在线观看 | 亚洲深夜| 久久精品视频一区 | 日韩一区二区三区四区不卡 | 无限观看社区在线视频 | 国产精品成人观看视频网站 | 日本一线a视频免费观看 |